The offering closes July 31, 2026, creating near-term overhang from the discounted placement and warrant overhang. The key catalyst is the October 30 PDUFA for INO-3107; failure to secure accelerated approval would likely force further dilutive financing or a strategic alternative. Monitor for FDA feedback on accelerated approval eligibility and any updates on the shareholder litigation.
Drug in focus
INO drug pipeline →VOCERYQ
● Neutral Named in this 424B5- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
- Next catalyst
- None dated
What to watchWith the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 31 $0.6770entry
- T+1 · 4mo ago +2.92%α +1.50% · $0.6968
- T+5 · 3mo ago −1.33%α −4.84% · $0.6680
- T+20 · 3mo ago +90.55%α +87.56% · $1.29
- T+60 · 22d ago +28.48%α +26.02% · $0.8698
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Inovio Pharmaceuticals (INO) is raising ~$18.3M net via a 424B5 takedown from its $300M shelf, selling 21.1M shares and warrants for 42.1M shares at $0.95/unit (a ~8% discount to the $1.03 close). The company also disclosed a going-concern risk, preliminary cash of $36.7M as of June 30, 2026, and that the FDA has not yet ruled on INO-3107's accelerated approval eligibility ahead of the October 30 PDUFA date. This offering adds ~30% immediate dilution from shares alone, with potential for further dilution from the 2:1 warrant coverage.
Key Facts
- Offering of 21,052,632 shares and warrants for 42,105,264 shares at $0.95/unit, raising ~$18.3M net ($20M gross)
- Warrants exercisable at $1.10/share for 5 years; no public market expected for warrants
- Pro forma as-adjusted net tangible book value per share of $0.58 vs. offering price of $0.95 = $0.37 immediate dilution per share
- Company discloses 'substantial doubt exists as to our ability to continue as a going concern'
- Preliminary cash and cash equivalents of ~$36.7M as of June 30, 2026
- PDUFA target date for INO-3107 BLA is October 30, 2026; FDA has not provided feedback on accelerated approval eligibility
- Shareholder class action (Feb 2026) and three derivative lawsuits filed against the company and officers
- Proceeds intended for potential commercial launch of INO-3107, confirmatory trial, pipeline development, and general corporate purposes
Financial Impact
Immediate dilution of ~30% from shares (21.1M new shares on ~69.8M pre-offering outstanding), plus potential additional dilution from 42.1M warrants (2:1 ratio) at $1.10 exercise price. Net proceeds of ~$18.3M extend runway into late Q1 2027 per management.
Risk Factors
- FDA may deny accelerated approval for INO-3107, requiring a costly Phase 3 trial or alternative path
- Warrant exercise at $1.10 (above current $1.03 price) is unlikely near-term, but cashless exercise could still add dilution
- Going-concern risk if capital is insufficient to fund operations through potential launch
- Shareholder class action and derivative lawsuits could result in material damages or management distraction
- Frequent capital raises (12 filings in 24 months) signal ongoing cash burn and potential for further dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-326370 |
| Document: 0001193125-26-326370-index-headers.html | 0001193125-26-326370 |
| Document: 0001193125-26-326370-index.html | 0001193125-26-326370 |
| Document: 0001193125-26-326370.txt | 0001193125-26-326370 |
Track record
20 reports on INO
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 8 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
- Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers